This could be one of the most undervalued stocks in SG this half year
The base case is simple: compliance demand is mandatory, not cyclical.
What stands out in this initiation note:
Testing is the base: high repeat business (85%+), lab testing dominates revenue (FY24: 93.6%)
ESG is the growth layer: Singapore’s mandatory climate disclosures (from FY2025) and Malaysia’s phased rollout expand third-party assurance demand
Financials are clean: FY24 net margin 20.5%, EBITDA margin 36%, with net cash (RM 9.8m)
The report’s anchor is clear: TP S$0.44 vs last S$0.35 (~+26%).
Not a hype story — more like a regulation-backed business still priced like a simple lab.
Which Singapore stock do you like most this half-year?
Leave a comment and we’ll break down the research.[财迷]
Modify on 2026-02-02 10:11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
